secwatch.observer — SEC 8-K summary
======================================

Issuer:     IRONWOOD PHARMACEUTICALS INC (IRWD)
CIK:        0001446847
Form:       8-K
Filed at:   2022-05-05T23:59:59+00:00
Accession:  0001104659-22-056130
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ironwood Q1 2022: LINZESS Rx demand +11%; net sales $232M; GAAP net income $39M
-------------------------------------------------------------------------------

- LINZESS U.S. net sales $232M (+8% YoY); prescription demand growth +11% YoY.
- Total revenue $98M; GAAP net income $39M ($0.21 diluted EPS).
- Adjusted EBITDA $58M, up from $46M; cash and equivalents $593M.
- Full-year 2022 financial guidance reaffirmed; LINZESS exceeded $1B in 2021.
- CEO cites progress in clinical trials and plans to in-license or acquire GI assets.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/0001104659-22-056130-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1446847/000110465922056130/tm2214395d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-056130

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer